Skip To Main Content
Campus
  • Utbildning
Campus
  • Utbildning
View Full Results

InRange publication

InRange diabetes type 1

CGM-based Time-in-Range Using Insuln Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled in Range Trial

Tadej Battelino MD, PhD,Thomas Danne MD,Steve V Edelman MD,Pratik Choudhary MD,Eric Renard MD,Jukka Westerbacka MD, PhD,Bhaswati Mukherjee MD,Valerie Pilorget MD,Mathieu Coudert MSc,Richard M Bergenstal MD

Diabetes Obes Metab. 2022; 1- 11. doi:10.1111/dom.14898

Read the Complete Publication Here

See the result of the InRange study here

Learn more about TiR, the study
design and result of InRange

Read More

Read the Complete Publication Here
Relaterade Artiklar
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Läs mer
Autoimmune Type 1 Diabetes

Autoimmune Type 1 Diabetes

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.1-4 

The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2

Läs mer
The Complex Burden of Autoimmune Type 1 Diabetes

The Complex Burden of Autoimmune Type 1 Diabetes

Läs mer